Abstract:Cystic fibrosis (CF) is a life‐limiting genetic condition, affecting over 90,000 people worldwide. CF affects several organs in the body, but airway damage has the most profound impact on quality of life (QoL) and survival. Causes of lower airway infection in people with CF are, most notably, Staphylococcus aureus in the early course of the disease and Pseudomonas aeruginosa at a later stage. Macrolide antibiotics, e.g. azithromycin and clarithromycin, are usually taken orally, have a broad spectrum of action against gram‐positive (e.g. S aureus ) and some gram‐negative bacteria (e.g. Haemophilus influenzae ), and may have a modifying role in diseases involving airway infection and inflammation such as CF. They are well‐tolerated and relatively inexpensive, but widespread use has resulted in the emergence of resistant bacteria. This is an updated review. To assess the potential effects of macrolide antibiotics on clinical status in terms of benefit and harm in people with CF. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals, and abstract books of conference proceedings. We last searched the Group's Cystic Fibrosis Trials Register on 2 November 2022. We last searched the trial registries WHO ICTRP and clinicaltrials.gov on 9 November 2022. We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow‐up data, where possible. We included randomised controlled trials of macrolide antibiotics in adults and children with CF. We compared them to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose or type of administration. Two authors independently extracted data and assessed risk of bias. We assessed the certainty of evidence using GRADE. We included 14 studies (1467 participants) lasting 28 days to 36 months. All the studies assessed azithromycin: 11 compared oral azithromycin to placebo (1167 participants); one compared a high dose to a low dose (47 participants); one compared nebulised to oral azithromycin (45 participants); and one looked at weekly versus daily dose (208 participants). Oral azithromycin versus placebo There is a slight improvement in forced expiratory volume (FEV 1 % predicted) in one second in the azithromycin group at up to six months compared to placebo (mean difference (MD) 3.97, 95% confidence interval (CI) 1.74 to 6.19; high‐certainty evidence), although there is probably no difference at three months, (MD 2.70%, 95% CI ‐0.12 to 5.52), or 12 months (MD ‐0.13, 95% CI ‐4.96 to 4.70). Participants in the azithromycin group are probably at a decreased risk of pulmonary exacerbation with a longer time to exacerbation (hazard ratio (HR) 0.61, 95% CI 0.50 to 0.75; moderate‐certainty evidence). Mild side effects were common, but there was no difference between groups (moderate‐certainty evidence). There is no difference in hospital admissions at six months (odds ratio (OR) 0.61, 95% CI 0.36 to 1.04; high‐certainty evidence), or in new acquisition of P aeruginosa at 12 months (HR 1.00, 95% CI 0.64 to 1.55; moderate‐certainty evidence). High‐dose versus low‐dose azithromycin We are uncertain whether there is any difference in FEV 1 % predicted at six months between the two groups (no data available) or in the rate of exacerbations per child per month (MD ‐0.05 (95% CI ‐0.20 to 0.10)); very low‐certainty evidence for both outcomes. Only children were included in the study and the study did not report on any of our other clinically important outcomes. Nebulised azithromycin versus oral azithromycin We were unable to include any of the data into our analyses and have reported findings directly from the paper; we graded all evidence as being of very low certainty. The authors reported that there was a greater mean change in FEV 1 % predicted at one month in the nebulised azithromycin group (P < 0.001). We are uncertain whether there was a change in P aeruginosa count. Weekly azithromycin versus daily azithromycin There is probably a lower mean change in FEV 1 % predicted at six months in the weekly group compared to the daily group (MD ‐0.70, 95% CI ‐0.95 to ‐0.45) and probably also a longer period of time until first exacerbation in the weekly group (MD 17.30 days, 95% CI 4.32 days to 30.28 days). Gastrointestinal side effects are probably more common in the weekly group and there is likely no difference in admissions to hospital or QoL. We graded all evidence as moderate certainty. Azithromycin therapy i -Abstract Truncated-

Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis

Safety of azithromycin in pediatrics: a systematic review and meta-analysis

Azithromycin. A review of its use in paediatric infectious diseases

Efficacy and safety of Azithromycin and Erythromycin for respiratory mycoplasma infection in children: a meta-analysis

The efficacy and safety of azithromycin in treatment for childhood asthma: A systematic review and meta‐analysis

The Efficacy and Safety of Azithromycin in Asthma: A Systematic Review

Clinical Efficacy of Azithromycin in the Treatment of Pediatric Mycoplasma pneumoniae Pneumonia and Its Impact on Platelet Count and D-Dimer Levels

Effect of Small Doses of Azithromycin on Pulmonary Ventilation Function and Inflammatory Factors IL-6, IL-13 in Children with Bronchial Asthma

Analysis on 198 cases adverse drug reaction/event reports of azithromycin

Azithromycin sequential therapy plus inhaled terbutaline for Mycoplasma Pneumoniae pneumonia in children: a systematic review and meta-analysis

The Timing Of Azithromycin Treatment Is Not Associated With The Clinical Prognosis Of Childhood Mycoplasma Pneumoniae Pneumonia In High Macrolide-Resistant Prevalence Settings

The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Long-Term Safety Profiles of Macrolides and Tetracyclines: A Systematic Review and Meta-Analysis

Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

Recommendations on Off-Label Use of Intravenous Azithromycin in Children.

Use and safety of azithromycin in neonates: a systematic review

Selection and Application Opportunity of Antibiotics in Children with Respiratory Tract Infections

Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia

Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials

Macrolide antibiotics (including azithromycin) for cystic fibrosis

Early target attainment of azithromycin therapy in children with lower respiratory tract infections